Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-Remitting Multiple Sclerosis”

Showing 20 of 0 results

Not applicableStudy completedNCT06129019
What this trial is testing

The Effect of Reiki Application on Depression, Anxiety and Physical Activity in Patient With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Ataturk University 60
Large-scale testing (Phase 3)Study completedNCT00459667
What this trial is testing

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Bayer 1,420
Large-scale testing (Phase 3)Study completedNCT00947752
What this trial is testing

Safety of New Formulation of Glatiramer Acetate

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 147
Not applicableStudy completedNCT01396343
What this trial is testing

Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis

Who this might be right for
Pediatric Multiple Sclerosis
University of California, San Francisco 1,276
Not applicableStudy completedNCT02687919
What this trial is testing

Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-remitting
Amanda Irish 31
Testing effectiveness (Phase 2)Ended earlyNCT04625153
What this trial is testing

RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
RemeGen Co., Ltd. 8
Large-scale testing (Phase 3)Study completedNCT00641537
What this trial is testing

CLARITY Extension Study

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
EMD Serono Research & Development Institute, Inc. 867
Not applicableNot Yet RecruitingNCT07645937
What this trial is testing

Effects of Low-Load Blood Flow Restriction Exercise on Rectus Femoris Muscle Morphology in Individuals With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remitting
Hanifi Bal 30
Not applicableStudy completedNCT02117375
What this trial is testing

EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients

Who this might be right for
Multiple Sclerosis
Rennes University Hospital 115
Testing effectiveness (Phase 2)Study completedNCT01890655
What this trial is testing

Extension Study of MT-1303

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Tanabe Pharma Corporation 367
Testing effectiveness (Phase 2)Study completedNCT00676715
What this trial is testing

The Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Genentech, Inc. 220
Not applicableStudy completedNCT01881191
What this trial is testing

Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months

Who this might be right for
Multiple Sclerosis
University at Buffalo 50
Not applicableStudy completedNCT02010554
What this trial is testing

Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS

Who this might be right for
Relapsing-remitting Multiple Sclerosis
University of Missouri, Kansas City 40
Large-scale testing (Phase 3)Looking for participantsNCT05758831
What this trial is testing

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

Who this might be right for
Multiple SclerosisRelapsing-remitting Multiple Sclerosis
Rennes University Hospital 386
Testing effectiveness (Phase 2)Ended earlyNCT01134627
What this trial is testing

Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany 305
Testing effectiveness (Phase 2)Study completedNCT00382629
What this trial is testing

BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Bayhill Therapeutics 252
Large-scale testing (Phase 3)Study completedNCT00292253
What this trial is testing

Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects

Who this might be right for
Multiple Sclerosis, Relapsing-remitting
EMD Serono 1,883
Large-scale testing (Phase 3)Study completedNCT00099502
What this trial is testing

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Bayer 2,244
Not applicableStudy completedNCT01233245
What this trial is testing

BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

Who this might be right for
Relapsing Remitting MS (RRMS)Secondary Progressive MS (SPMS)
Bayer 1,077
Not applicableActive Not RecruitingNCT06095271
What this trial is testing

MultiSCRIPT-Cycle 1: Personalized Medicine in Multiple Sclerosis - Pragmatic Platform Trial Embedded Within the SMSC

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University Hospital, Basel, Switzerland 920
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation